Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
JAMA Network Open|July 1, 2026
Breast Cancer Survival in Asian American PatientsScarlett Lin Gomez, Julie Von Behren, Valerie McGuire, et al.
Breast Cancer Research and Treatment|July 6, 2025
Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancerJenna Bhimani, Peng Wang, Grace B Gallagher, et al.
JCO Clinical Cancer Informatics|April 18, 2024
Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast CancerJenna Bhimani, Kelli O'Connell, Isaac J Ergas, et al.
Breast Cancer Research : BCR|June 13, 2024
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019Jenna Bhimani, Kelli O'Connell, Isaac J Ergas, et al.
International Journal of Cancer|June 2, 2025
Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancerJenna Bhimani, Peng Wang, Grace B Gallagher, et al.
Cancer|March 11, 2026
The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Victoria S Blinder, et al.
Journal of the National Cancer Institute|November 3, 2025
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancerErin J Aiello Bowles, Kelli O'Connell, Jenna Bhimani, et al.
Breast Cancer Research and Treatment|August 16, 2024
The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery systemJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
JCO Oncology Practice|December 11, 2025
Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast CancerYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
NPJ Breast Cancer|October 30, 2025
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Grace B Gallagher, et al.
Pageof 7